Lipidor Reports Positive Phase I/IIa Data In Psoriasis


Lipidor has reported positive results from a Phase I/IIa study investigating the efficacy and tolerability of its Akvano/calcipotriol spray formulation for the treatment of psoriasis vulgaris.

The primary objective of the trial was met since Akvano/calcipotriol showed clear and significant antipsoriatic effects, measured by sonography as a reduction in infiltrate thickness, in comparison to corresponding vehicle formulations. A secondary objective was also met since the antipsoriatic effects were comparable to that of the marketed product, Daivonex (calcipotriol) solution. Twenty-four patients (male and female) were included in the study, receiving ten topical treatments over 12 days. No safety issues were noted in the study.

Lipidor is developing Akvano/calcipotriol, a water-free spray formulation containing calcipotriol, a vitamin D derivative that is one of the cornerstones in the treatment of mild-to-moderate psoriasis vulgaris. The Akvano technology enables efficient delivery of the pharmaceutical ingredient. After application, the carrier compound evaporates quickly, leaving a pleasant feeling on the skin and a cosmetically appealing result. The company is also evaluating a similar Akvano-based product concept with a combination of calcipotriol and a corticosteroid for the same indication.

This article is tagged to:
Sector: Pharmaceuticals & Healthcare, Medical Devices
Geography: Sweden